The vision of personalised medicine is to use an individual’s clinical, genomic, or other biomarker information to more precisely and accurately select a medication and its dose for each patient, improving healthcare and lowing costs.
EPEMED aims to recruit members from across the diagnostic, pharmaceutical, device, and academic communities as well as patient groups and professional service firms. Its goals are to:
Move the field of personalised medicine forward across Europe through targeted education and sharing of ideas and business models
Provide opinion leadership on policies related to personalised medicine in Europe
Promote harmonisation in the approach to personalised medicine at a European level
Create joint programmes with other international personalised medicine organisations
EPEMED was founded and is chaired by Alain Huriez of TcLand Expression, a French Molecular Diagnostic company. The association will focus initially on educating the public, governments and private sector on the importance and benefits of personalised medicine diagnostics.
EPEMED’s first mission is to foster the adoption of high value, high quality standardised advanced diagnostics in support of personalised medicine in Europe, to inform pricing and reimbursement negotiations and ensure there is a clear regulatory path in Europe for novel diagnostics and/or companion therapeutics.
The association’s founding board of directors are:
Alain Huriez, Chairman, CEO TcLand Expression
Mara Aspinall, President & CEO, On-Q-ity, and former president, Genzyme Genetics
Vincent Fert, President & CEO Ipsogen
Werner Kroll, Head Diagnostics Research and Innovation, Novartis Molecular Diagnostics
Iain D. Miller, Ph.D., Senior Director, Oncology Strategy and Theranostics, bioMerieux
Herman Spolders, BVBA, CEO Oncomethylome Sciences
Patrick F. Terry, founder Genomic Health & PMC, CEO Technic Solutions
“It is now time for European players in the field of personalised medicine and high-value diagnostics to join forces to shape the environment and accelerate access of their innovations in Europe” said Huriez.
“The next few years will see deep changes in medical care due to the development of breakthrough innovations in the field of molecular diagnostics that will help clinicians in better treating their patients. It is our responsibility to make sure that these innovations will be made available to European patients and as a result, to make Europe an attractive place for innovations, financial and industrial investments in the area of personalised medicine diagnostics.”
For more information, visit http://www.epemed.org.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.